ORIC presents enozertinib Phase 1b update; no specific results in filing

Oric Pharmaceuticals, Inc.

Company announced enozertinib (ORIC-114) program update on December 6, 2025.
Update covers data from Phase 1b trial; presentation attached as Exhibit 99.1.
No efficacy or safety figures included in the filing text itself.
Investors must refer to the separate presentation for detailed data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.